Peter Manley

NGM Biopharmaceuticals (United States) — United States

Medicine · Health Sciences

34h-index4.2kcitations129works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(69), Neuroblastoma Research and Treatments(29), Childhood Cancer Survivors' Quality of Life(23), Pituitary Gland Disorders and Treatments(12), Meningioma and schwannoma management(10)

Publications123 total

CTP-17. Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial
Neuro-Oncology·2025Open Access
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine·2025Open Access
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Neuro-Oncology·2024· 7 citedOpen Access
CTNI-09. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
Neuro-Oncology·2024Open Access
NCOG-05. HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Neuro-Oncology·2024Open Access
Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19
JACC. Cardiovascular imaging·2024· 5 citedOpen Access
LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL
Neuro-Oncology·2024· 1 citedOpen Access
Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.
Journal of Clinical Oncology·2024· 2 cited
Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records
Neuro-Oncology Practice·2024· 4 citedOpen Access
The long-term impact of cerebellar tumor resection on executive functioning, anxiety, and fear of pain: A mixed methodology pilot study
Applied Neuropsychology Child·2024Open Access
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine·2024· 4 citedOpen Access
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
BMC Cancer·2024· 51 citedOpen Access
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine·2023· 147 citedOpen Access
CTNI-37. CLINICAL ACTIVITY OF RAF INHIBITOR TOVORAFENIB ACCORDING TO PRIOR MAPK INHIBITOR TREATMENT IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
Neuro-Oncology·2023· 1 citedOpen Access
CTNI-24. CLINICAL ACTIVITY AND SAFETY OF THE RAF INHIBITOR TOVORAFENIB IN PATIENTS WITH OPTIC PATHWAY GLIOMAS IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
Neuro-Oncology·2023· 1 citedOpen Access
LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
Neuro-Oncology·2023· 2 citedOpen Access
Healthcare resource use for pediatric low-grade glioma care: A cohort of linked electronic health records and claims data.
Journal of Clinical Oncology·2023· 1 cited
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Journal of Clinical Oncology·2023· 13 cited
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating <i>RAF</i> alteration.
Journal of Clinical Oncology·2023· 4 cited
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Nature Medicine·2023· 95 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Mark W. Kieran(20), Liliana Goumnerova(16), Nicole J. Ullrich(16), Susan Chi(15), Stewart Goldman(9), Karen J. Marcus(9), Pratiti Bandopadhayay(8), Christine Chordas(8), Nathan Robison(7), Christopher J. Recklitis(7), Cori Liptak(6), R. Michael Scott(5), Keith L. Ligon(5), Wendy B. London(5), Rameen Beroukhim(4), Hayley Malkin(4), Sandro Santagata(3), Anne Bendel(3), Guillaume Bergthold(3), Dongjing Guo(3)